Keun Seok Lee - Concepedia

Author

Keun Seok Lee

National Cancer Center ORCID

Also Known As

In Hae Park, Japan, K Seok Lee, K.S. Lee, Keun Seok Lee, Keun-Seok Lee, Lee, Keun Seok, Seeyoun Lee, Yeon Hee Park

340

Publications

14.1K

Citations

H-Index

108

Concepts

All Affiliations

National Cancer Center Asan Medical Center Seoul National University Hospital University of Ulsan Ulsan College

About

Keun Seok Lee is an author at National Cancer Center specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	57	5.6K
2	Health Sciences	17	18	1.7K
3	Nursing	2	2	149
4	Engineering	1	1	36
5	Public Health	1	1	11

Keun Seok Lee

126

Publications

12.9K

Citations

H-Index

Page 1

	Year	Citations
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer Shanu Modi, William Jacot, Toshinari Yamashita, New England Journal of Medicine	2022	2.3K
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer Shanu Modi, Cristina Saura, Toshinari Yamashita, New England Journal of Medicine	2019	1.9K
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial Debu Tripathy, Seock‐Ah Im, Marco Colleoni, The Lancet Oncology Advanced Breast CancerBreast OncologyOncologyEndocrine OncologyMedicine	2018	973
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer Keun Seok Lee, Hyun Cheol Chung, Seock Ah Im, Breast Cancer Research and Treatment Metastatic Breast CancerBreast OncologyPolymer-drug ConjugateMedicinePharmacology	2007	518
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial Eric P. Winer, Oleg Lipatov, Seock‐Ah Im, The Lancet Oncology Breast OncologyOncologyClinical TrialsPathologyImmune Checkpoint Inhibitor	2021	469
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im, The Lancet Oncology First-line TherapyBreast OncologyMedicinePharmacologyClinical Trials	2017	463
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial Angelo Di Leo, Stephen Johnston, Keun Seok Lee, The Lancet Oncology Advanced Breast CancerBreast OncologyOncologyMedicineGynecology	2017	377
Clinical Implications of CYP2D6 Genotypes Predictive of Tamoxifen Pharmacokinetics in Metastatic Breast Cancer Hyeong‐Seok Lim, Han Ju Lee, Keun Seok Lee, Journal of Clinical Oncology	2007	268
Breast cancer subtypes and survival in patients with brain metastases Byung‐Ho Nam, Sun Young Kim, Hye‐Sook Han, Breast Cancer Research	2008	227

Page 1